The Disruptor26 Podcast Series with Paul Garofolo
Locus Biosciences is revolutionizing the treatment of bacterial disease using its CRISPR-Cas3 technology to kill targeted bacteria while leaving the many species of good bacteria in the body unharmed. Listen to Kineticos Founder and CEO Shailesh Maingi and Paul Garofolo, CEO of Locus Biosciences as they discuss the past, present, and future of Locus Biosciences … Continue reading The Disruptor26 Podcast Series with Paul Garofolo
2020 Q1 BCI – Fundamentals of Running a Biopharmaceutical
The Biopharma CEO Confidence Index is a forward-looking indicator designed to measure C-suite sentiment and confidence in the biopharma industry’s economy. The BCI measures c-suite and executive leadership sentiment in the biopharma industry asking questions about their confidence levels concerning key issues. We look for the BCI to become a valuable and highly sought-after resource for … Continue reading 2020 Q1 BCI – Fundamentals of Running a Biopharmaceutical
What Can China Teach Us About CAR-T?
What Can China Teach Us About CAR T is the final installment of our CAR-T series and discusses how China has embraced CAR-T therapy. Our panelists also touch on how China and the US can grow off of each other’s strengths. Moderator Shailesh Maingi, Founder and CEO, Kineticos Panel Members Bill Farley, VP of Business … Continue reading What Can China Teach Us About CAR-T?
Staying the Course
Written by Mark Osterman, Senior Vice President, Kineticos Kineticos recently announced Q4 2015 results of the Biopharma CEO Confidence Index, which showed a tempering of enthusiasm among biopharma CEOs compared to the Q3 2015 study. The results of the Q4 index, which is intended to serve as an indicator of CEO sentiment in the biopharma … Continue reading Staying the Course
Cell and Gene Therapies: The Path to Commercialization
Article Preview Regenerative Medicine holds enormous potential for treating and ameliorating many chronic conditions for which we do not yet have viable treatment options, with the potential to address ever-increasing medical costs and improve the quality of life of countless sufferers and their families. However, the challenges associated with developing and delivering these therapies are daunting, … Continue reading Cell and Gene Therapies: The Path to Commercialization
Bridges and Barriers to Advancing CAR T Therapy
One result of the Oncology explosion over the past 10 years has been the advent of CAR T therapy. In fact, we have seen two recent approvals, both for hematological cancers. Yet, the industry has not made nearly as much progress in solid tumors. Kineticos’ Operating Executive, Steve Buckanavage, recently caught up with Dr. Jeffrey Skolnik, VP … Continue reading Bridges and Barriers to Advancing CAR T Therapy
Corporate Strategy services apply our experience and industry knowledge combined with benchmarks and competitive analysis to help biopharmaceutical companies make critical decisions about the direction of their business as well as their product portfolio.
Service lines include:
Business Model Design
Geographic Market Entry
Click the Tabs Below for Corporate Strategy Case Studies, White Papers & Articles, and Blog
Growth by Acquisition in Life Sciences: Do You Have a Plan?
Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as Roche’s acquisition of Ariosa Diagnostics and LabCorp’s acquisition of Covance, bring to light an important question for decision makers in the life sciences industry: When it comes to growth by acquisition, what is your plan? … Continue reading Growth by Acquisition in Life Sciences: Do You Have a Plan?
R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation
James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation?
Merck KGaA and Bayer Choose Opposite Strategies
Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent blogs, Merck KGaA and Bayer are both responding to the basic core of their original strategies—Merck KGaA is acquiring Sigma-Aldrich to diversify their materials and services and Bayer is “spinning-off” (and eventually selling, over the … Continue reading Merck KGaA and Bayer Choose Opposite Strategies
Foundation Medicine and Clovis Expand Partnership
Article Preview In April 2014, Foundation Medicine and Clovis Oncology announced the expansion of their partnership by developing a companion diagnostic for a Clovis drug currently in clinical trials.1 Specifically, the test is being developed in conjunction with the FDA new drug application submission for Rucaparib, a polymerase inhibitor for the treatment of…
Role of Companion Diagnostics in Immuno-oncology Race Unfolding
Article Preview Important oncology events, including ASCO and ESMO, have recently displayed the fruits of the huge investment drug companies have put into oncology, especially the immuno-oncology therapies centered on PD-1. In previous blogs, I noted that BMS appeared to be leaning toward not incorporating a companion diagnostic for nivolumab (another anti-PD-1 therapy) in melanoma … Continue reading Role of Companion Diagnostics in Immuno-oncology Race Unfolding
Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity
Article Preview As reported by Bloomberg and the Wall Street Journal, Bayer is expected to announce plans to sell its plastics unit, creating a key shift from chemicals to the life science industry. Along with Merck KGaA, Bayer is one of Europe’s last foremost drug and chemical multinationals, making the shift unprecedented, if not unexpected. … Continue reading Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity